These Are The Top 10 Happiest Cities In The World, As Per Happy City Index Report 2025
Don't know how to keep things happy-go-lucky? It's time to relocate to Copenhagen. Known for its Michelin-starred food and colourful canal houses, the Danish capital has been named the happiest city on Earth. Courtesy: Happy City Index. Each year, the Institute for Quality of Life releases this index, ranking cities based on access to open spaces, inclusive policies, education, the economy, and environmental protection. Overall, the organisation looks at 82 different indicators of joy, including individual interviews with residents in cities across the globe.
Also Read: 6 Countries With The Best Public Transportation Systems
Here is the list of the top 10 happiest cities in the world for 2025:
1. Copenhagen, Denmark
Ranked as the happiest city in the world, Copenhagen "seamlessly blends history, modernity, and sustainability," stated the index. Denmark's capital received great points for emphasising education and innovation. Furthermore, the city prioritises work-life balance, with an average work week of only 37 hours. The city also provides a plethora of eco-friendly transportation, clean air and plenty of green spaces.
2. Zurich, Switzerland
Zurich comes in second on the list. The city is renowned for its superb public services, robust economy, and tranquil atmosphere. "The city is one of the wealthiest urban centres in the world, with average earnings that are 75 per cent higher than the national average," the report said. "Zurich maintains one of the safest road networks, with a traffic-related fatality rate of just 0.07 per 10,000 residents," it further added.
3. Singapore
Singapore secured the third position in the list. With 0.62 parks per square kilometre and a high percentage of sustainable transit alternatives, the city places a high priority on the environment. Singapore's life expectancy is 83 years, and 15% of adults receive integrated mental care.
4. Aarhus, Denmark
Due in great part to its emphasis on health and education, Aarhus, the second-largest city in Denmark, is ranked fourth on the list. There are 4.4 doctors per 1,000 residents, and all residents have health insurance. People here have generally healthy lives, with a balanced 37-hour workday and an 81.3-year life expectancy.
5. Antwerp, Belgium
Antwerp is next in the list. Perched on the banks of the Scheldt River, the city has received top marks for transportation, healthcare, and education. 82 years is the average lifespan, seven per cent of the population pursues lifelong learning, and twenty-eight per cent have a master's degree.
6. Seoul, South Korea
A vibrant city renowned for its fusion of modernity and culture, Seoul comes in sixth on the list. The city has state-of-the-art infrastructure and technology in addition to a rich cultural legacy. An effective public transportation system and emphasis on education contribute to a high quality of life.
7. Stockholm, Sweden
Stockholm is popular for its beautiful archipelago and dedication to sustainability. With first-rate public services and a robust social welfare system, the city provides a high standard of living. A healthy lifestyle is encouraged by the city's emphasis on green areas and outdoor activities.
8. Taipei, Taiwan
Known for its technical innovations and inventiveness, Taipei offers its citizens a wide range of opportunities. A high standard of living is supported by its state-of-the-art infrastructure and effective public services. Numerous internationally recognised colleges and educational establishments may be found in Taipei, drawing students from all over the world.
9. Munich, Germany
Munich offers a range of public amenities and services to its citizens that contribute to a high standard of living. The city's robust economy is fueled by a variety of industries, including industrial, banking, and technology. Residents benefit from a wealth of employment possibilities and economic success brought about by the presence of many global corporate headquarters.
10. Rotterdam, Netherlands
Rotterdam is known for its vibrant cultural scene and contemporary architecture. The city provides a wide range of public amenities and services that help its citizens live well. Additionally, Rotterdam aggressively works to encourage the use of renewable energy sources and lower carbon emissions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
4 days ago
- India.com
Looking For A Coastal Escape? Check Out These 5 Famous Beaches Near Thanjavur
You know how Thanjavur is all about history temples and culture right But what most people don't talk about is that some really cool beaches are not too far from the city. Like, if you've been stuck in the temple trail and need a little break, just pack your bag and head out for a few hours. You'll find places with soft sand calm waves and even some old stories waiting for you. These aren't the crowded beaches of Goa or Mumbai. These are quiet spots where you can sit back breathe fresh air and maybe even learn something new while enjoying the view. Beach Nagapattinam Beach is about 85 kilometers away from Thanjavur. Popular for its peaceful atmosphere and natural beauty, this beach attracts locals as well as tourists who desire to have some rest time. Swimming can be done here because the water is clear with clean sand on this beach. Also around Nagore Dargah is there which is an ancient man made place that adds people's visitation a bit more historically significant. Beach Kodikkarai Beach or Point Calimere lies approximately 110 kilometers away from Thanjavur. Flora and fauna diversity defines Point Calimere Wildlife and Bird Sanctuary where this beach also forms part of it. On one hand, the beach has amazing wildlife; on the other hand, it has lovely landscapes too. Birds migrate at different times in a year; wild horses among others are seen within this reserve area by visitors coming around here. For those who seek tranquility or tiredness against urban chaos it remains so in contrast with other crowded beaches. Beach The Poompuhar Beach is roughly 120 kilometers away from Thanjavur City Centre (Distance between poompuhar beach & thanjavur). This was one of Kaveripoompattinam ancient Chola port cities before it vanished into Indian Ocean waters over nine centuries ago (Marvelous Poompuhar). The historical significance as well as archaeological remnants marks this coast off (Thamizhagam). The Silappathikaram Art Gallery that displays scenes from the epic of Tamil, Silapathikaram is a must visit for any tourist coming to this place. As for the beach itself, people can spend time there comfortably walking, having a relaxing picnic and enjoying the coastal breeze. Beach Thanjavur is about 105 Kilometers away from Tharangambadi Beach. It is also known as Tranquebar which has a rich Danish colonial history (Facts about Tharangambadi or Tranquebar). Dansborg fort located on the beach was established by the Danish in the 17th century. Visitors are invited to explore the fort grounds, stroll along the beach and view unique combinations of Danish and Tamil architecture. Given its serene atmosphere and historical value, it remains one of most picturesque destinations. Beach This beach is at Karaikal approximately 110 kilometers from Thanjavur, a union territory in Puducherry (Geography of Thanjavur District; About Karaikal; A complete travel guide for your trip to Pondicherry). Here visitors find peace while swimming through clean water with fine sand along this part of India's coast. The beach offers excellent opportunities for swimming, sunbathing or leisurely picnics. While other attractions include Karaikal Ammaiyar Temple nearby and French Quarter where you will experience a mix of two cultures: Indian and European. When compared with others in many parts of the world, it does not attract too many people who just want to relax after working hard all week long. Final Thoughts The closeness of Thanjavur to the East coast of Tamil Nadu provides beach lovers with a wide range of options to explore and enjoy some of the most beautiful and peaceful seaside in this area. Each destination whether it is pilgrimage and serenity Velankanni Beach, historic Poompuhar Beach, wildlife and nature beauty Kodikkarai Beach or colonial charm Tharangambadi beach offers something special. These beaches are an ideal break from the rich cultural background as well as history of Thanjavur where visitors can relax, unwind and get in touch with nature.
Mint
4 days ago
- Mint
Ozempic, a patent challenge, and the $25 billion race for India's weight-loss drug market
Mumbai: In late May, Dr. Reddy's Laboratories, a pharmaceutical company from Hyderabad, sprang a surprise. It filed a patent challenge against Novo Nordisk, a Danish company, for its popular weight loss drug semaglutide. Novo Nordisk filed for two patent applications in India—in 2006, which expired in September 2024, and another in 2007, which is set to expire in March 2026. Dr. Reddy's has challenged the second patent, contending that it lacks novelty. Pharma companies often file follow-on patents with claims of modifications to the original compound and its derivative forms. The follow-on patents allow drug developers to extend their market monopoly and halt generic competition for longer. Generic versions are cheaper copies of the original drug. Dr. Reddy's, obviously, is in a hurry to launch a generic version. A win for the company will upend the plans of more than a dozen local pharmaceutical firms, all of whom are eyeing a slice of the estimated $25 billion Indian weight loss market. No prescription drug in recent memory has captured the imagination of Indian patients as much as semaglutide. Or for that matter globally. In 2024, sold under three brand names—Ozempic, Wegovy and Rybelsus—semaglutide is the second most prescribed drug in the world, notching sales of $29 billion annually. A more recently launched competing brand, Mounjaro, by US-headquartered drug maker Eli Lilly, grew 123% in 2024 to $11.5 billion and is already among the top 10 drugs in the world, according to Drug Discovery & Development, a pharmaceutical industry news website. 'It's a big opportunity. It's a product that comes once in a while in the pharma cycle, and perhaps a product that people are a lot more aware of, much before its launch," Umang Vohra, managing director and global CEO of Cipla, told journalists during an interaction last month. Social media has contributed immensely to the street popularity of Ozempic, largely driven by celebrity endorsements by the likes of Oprah Winfrey and Elon Musk. Both admitted to using such drugs to manage their weight. Though Indian celebrities haven't yet admitted to their use, the mystery slimming of Bollywood film maker Karan Johar and TV talk show host Kapil Sharma have drawn comparisons. Opportunity 2.0 Nonetheless, it is not all social media. There is a genuine market for weight loss medications—numbers tell the story. A recent Lancet study stated that India is expected to total 450 million overweight or obese people by 2050, the largest in the world. The study also found that obesity rates increased from 1.2% in 1990 to 9.8% in 2022 for women and 0.5% to 5.4% in men. Those with body mass index (BMI) between 25 kg/m2 to 29.9 kg/m2 are considered overweight while those with an index of over 30 kg/m2 are considered obese. 'Often, lifestyle diseases are associated with adults but we must not overlook the increasing issues of overweight and obesity in juveniles. It is a growing menace," said Dr Sambit Patnaik, a Mumbai-based surgeon. The pharmaceutical industry has also spotted a rare opportunity, similar to the one it saw in anti-diabetic drugs at the turn of the century. At that time, the Indian pharmaceutical market, according to market research agency MARG, was all of ₹16,000 crore and diabetic drugs accounted for about ₹1,000 crore of it. Today, the market for diabetic drugs is worth ₹40,000 crore and it accounts for roughly 10% of the ₹4 trillion Indian industry. Back then, the boom was aided by the generic version of metformin, an oral drug with lower gastric side effects for type 2 diabetes. It caught the fancy of Ranbaxy Laboratories, Dr. Reddy's, Glenmark Pharmaceuticals and a host of other Indian pharmaceutical companies. Like diabetes drugs, weight loss medications also have to be taken as long as a patient wants to manage her or his weight—which explains the current gold rush. Crash the price In India, generic versions can cut current prices substantially, thereby expanding the market. Novo Nordisk's Rybelsus is available in India but only in oral form and a month's supply costs ₹10,000. The most effective form of the drug is as an injectable, and it is delivered in metered doses using a pen-like device with thin hair like needles. Imports can cost upwards of ₹80,000 per month. The injectable version is expected to launch soon. Despite the high costs, Rybelsus sales have notched up ₹418 crore, between its launch in 2022 and March 2025, according to Pharma data agency IQVIA. Mounjaro's injectables, available in India, cost far less— ₹17,500 per month. 'Since India sells branded generic dosages, the retail price of new launches will be 40-70% of the innovator's price," Ravinder Singha, managing director of Firmlink Pharma, a generic exporter, said. 'But since Mounjaro is the benchmark treatment, we should expect semaglutide drugs to be substantially cheaper," he added. Semaglutide tablets, therefore, could be available for ₹4000- ₹7000 per month and Wegovy clones at a bigger discount to Mounjaro's ₹17,500 per month. 'Generic brands in India will hit the shelf the next day a drug goes off patent," said Nimish Mehta, founder of Research Delta Advisors, a pharma consultancy. So, Indian generics should be available from April 2026 onwards. Meanwhile, Indian pharmacies have acknowledged the growing demand for such drugs. 'These GLP-1s…everyday we are selling huge quantities," Shobana Kamineni, executive chairperson of Apollo Health Co and Apollo Pharmacies, said. Medications used to treat obesity and type 2 diabetes are classified as GLP-1 (glucagon-like peptide-1) drugs. The science GLP-1 is an equivalent of peptide glucagon that is produced in the small intestine and colon after ingestion of food which increases blood sugar. Glucagon then stimulates the pancreas to produce insulin to control blood sugar. GLP-1 drugs behave like synthetic glucagon and stimulate the same effects from the body. In addition, GLP-1 drugs leave the user with a feeling of fullness that sends a message to the brain to slow down the ingestion of food. From the last decade, there is enough evidence that the new class of GLP-1 drugs, like semaglutide and tirzepatide, offer weight reduction between 21-23% of the initial body weight without any severe side effects. And as anti-diabetic drugs, they were meant for prolonged use. 'In the range of medication for management of obesity, (GLP-1s) have proven to be the game changer," bariatric surgeon Dr Muffazal Lakdawala told Mint. Historically, GLP-1 class of drugs did not see much competition for two reasons. Initially, these drugs were marketed as an anti-diabetic injection—there were already many competing drugs available in that space. Second, glucagon being a peptide hormone, an organic substance, the drugs had to emulate their form and structure. Like insulin, they can be produced by fermentation or by chemical synthesis and both have their complexities. Producing large quantities of fermentation medicines like insulin or penicillin require high investments, both in manufacturing and cold supply chains. Even in the oral version of semaglutide, which is manufactured by chemical synthesis, the manufacturing process is a long and complex one. Oral delivery of peptides does not permeate the gastrointestinal tract easily and, therefore, Novo Nordisk had to engineer its product differently to ensure potency. US dreams Despite all the complexities, Indian companies want to grab the opportunity the US, global and Indian markets present. Let's look at the US first. Companies like Sun Pharma, Dr. Reddy's, Lupin and Natco Pharma (which has a tie-up with Mylan Pharmaceuticals) filed applications with the US Food and Drug Administration (FDA) to make the generic versions of semaglutide the same month—December 2021. They did so to avail what is called the first-to-file (FTF) status. Overall, 18 Indian companies have applied. Generic applications in the US are filed way before patents expire and an FTF allows a company to market its generic for 180 days exclusively in the US, before more cheaper generics hit the market. Natco (through Mylan) is the only company to have sought approval for generic Wegovy. The US FDA has not yet approved any generic so far. 'Since an application to the FDA will include a sample of the product and details of manufacturing plants, we can assume that there is enough confidence among Indian players to make the drug," Mehta of Research Delta Advisors said. India stack A long list of companies, from different pharma sub-sectors, could benefit from the weight-loss bonanza. For the domestic market and for generic exports to countries where no patents exist, the list of companies waiting to launch semaglutide next year includes Dr. Reddy's, Sun Pharma, Cipla, Zydus Lifesciences, Lupin, Mankind Pharma, Alkem Laboratories, Biocon, Aurobindo Pharma, Natco and Torrent Pharmaceuticals among others. Zydus Lifesciences is working on a single pen device in multiple strengths, The Economic Times reported last month. It is also working on a novel formulation for semaglutide to commercialize in India and other markets. 'We are on track for day one launch in India," managing director Sharvil Patel told investors during an earnings call last month. Cipla, meanwhile, is eyeing the launch of GLP-1s through partnerships as well as through its own generic version. In a post-earnings media interaction recently, the company's managing director and global CEO Umang Vohra said: 'I think the biggest opportunity for us, at least, would continue to be the Indian market." Biocon has already launched another GLP-1, liraglutide, in India earlier this month. 'Our strategy is to offer liraglutide at competitive prices, aligned with local healthcare economics to maximize patient access in India," a company spokesperson told Mint in an email response. Biocon plans to launch semaglutide in India mid-next year, CEO Siddharth Mittal had told Mint in an earlier interview. The company now plans to expand its manufacturing capabilities to ensure supply reliability, it said in the emailed response. Sun Pharma and Mankind are also working on their own novel anti-obesity drugs. Sun Pharma is working on a novel GLP-1 GL0034 called utreglutide, which will likely be commercialized by the end of this decade. Mankind's drug candidate, GRP119, is currently in phase 2 trials in Australia. For the generic version of semaglutide, the company is banking on its salesforce and reach to give it a competitive edge, managing director Rajeev Juneja told Mint in an earlier interview. 'Any doctor would want to prescribe it, because now people know that there is something called Mounjaro, or semaglutide or Ozempic," Juneja said. 'We, by default, have a natural advantage because we have the deepest coverage, we have the maximum number of people working in each division," he added. Further, players like Divi's Laboratories, a manufacturer of active pharmaceutical ingredients, and Syngene International, a contract research, development and manufacturing company, can also benefit from the gold rush. 'Divi's Laboratories will be a key beneficiary in GLP-1 manufacturing as it makes several components in the peptide sequence," Shrikant Akolkar, head of pharmaceutical research at Nuvama, a brokerage, said. OneSource Specialty Pharma, the contract development and manufacturing arm of Strides Pharma, is among the few companies with end-to-end capabilities for GLP-1s—from formulation to device assembly. 'The most complex part of the whole value chain is to assemble the pen devices," OneSource Pharma's CEO, Neeraj Sharma, told Mint during a recent interaction. Another company, Vadodara-based Shaily Engineering Plastics, says it is nearly doubling its manufacturing line to make injectable pens—from 45 million to 85 million—funded by customer advances. A caution Clearly, speed to market will separate the winners from the also-rans. 'Early movers among the Indian players stand a good chance to benefit from GLP-1," said Akolkar. A recent report by Nuvama put a buy on Dr. Reddy's and Divi's Laboratories and a hold on Natco Pharma based on their GLP-1 play. Nonetheless, some doctors fear misuse of the drug because of its popularity. A prescription for diabetic drugs can be written by any medical practitioner. Weight loss clinics in the unorganised sector could start dispensing the drug for cosmetic purposes. For instance, a person in her 20s, who is slightly overweight, may be tempted to use these drugs instead of trying to lose weight by making lifestyle changes. 'We need some regulations to prevent over-the-counter use for weight loss," Dr Muffazal Lakdawala said. 'It is a hormonal drug so you have to be a little careful."
NDTV
4 days ago
- NDTV
Owners Of Former Michelin Star Restaurant In Japan Arrested After 80 Cases Of Food Poisoning
Owners of a popular restaurant in Japan have been arrested after nearly 80 diners reported coming down with food poisoning after eating food from the restaurant. Kiichi, a restaurant in Japan's Osaka Prefecture, is run by family members Hirokazu Kitano, 69, his wife Noriko, 68, and son Hirotoshi, 41. All three of them were arrested on June 16, 2025. Authorities suspect that they violated the Food Sanitation Act, which requires food establishments to implement basic hygiene and safety standards, reported the New York Post. In early February, Kiichi was ordered to suspend its services after 33 customers reported symptoms aligning with food poisoning and norovirus, including diarrhoea, stomach pain and vomiting. As per reports, despite the order to suspend the services, the restaurant allegedly continued to operate behind closed doors. They sold 11 traditional Japanese lunch box meals on February 16, 2025, that were contaminated with pathogenic microorganisms, according to the investigators. Norovirus was detected in the restaurant's food for a second time, and 23 diners reported food poisoning in February. The restaurant's suspension was extended through March. Police suspected that the food poisoning and norovirus cases were a result of poor management. The restaurant finally admitted to not enforcing strong hygiene practices. In late March, it wrote on its website, "We take this series of incidents seriously and deeply regret it. We will work to ensure food safety by strengthening and thoroughly implementing our hygiene management system to prevent a recurrence." Kiichi was honoured with a Michelin star for the Kansai region during the 2010s, but the restaurant was later removed from the prestigious list.
